Michael Sassano was an early investor in the United States cannabis industry and now heads SOMAÍ Pharmaceuticals, a next-generation biotech company centered on the cultivation, manufacturing, and distribution of GMP-certified cannabinoid-containing pharmaceutical products throughout the European Union. SOMAÍ opened Europe’s largest cannabis manufacturing facility earlier this year in Lisbon, Portugal.
Michael Sassano is one of the most respected executives in the pharmaceutical cannabis space today. He was an early investor in the cannabis industry in the United States; today he is celebrated in mainstream business and biopharma media as an international authority on developing large-scale cannabis infrastructures throughout the world and the most advanced pharmaceutical cannabinoid products. Michael is also widely respected for successfully predicting long-term cannabis market trends and movements, which he generously shares in many forums.
